Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia

Haematologica

Volumn 90, Issue 6, 2005, Pages

  Sanz, Miguel A ^a   Lo Coco, Francesco ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

ALK1; Angiogenesis; Hereditary hemorrhagic telangiectasia (HHT); TGF 1; VEGF

Indexed keywords

ANALGESIC AGENT; ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; DEXAMETHASONE; GEMTUZUMAB OZOGAMICIN; MANNITOL; METHOTREXATE; METHYLPREDNISOLONE; OSMOTIC DIURETIC AGENT; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANGIOGENESIS; BRAIN PSEUDOTUMOR; CHILD; COMORBIDITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FLUORESCENCE IN SITU HYBRIDIZATION; HEADACHE; HUMAN; INTRACRANIAL HYPERTENSION; KARYOTYPING; LEUKEMIA RELAPSE; LUNG INFILTRATE; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; NAUSEA; PAPILLEDEMA; PERICARDIAL EFFUSION; PREGNANCY; PROMYELOCYTIC LEUKEMIA; PROPHYLAXIS; RENDU OSLER WEBER DISEASE; RETINOIC ACID SYNDROME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT PLANNING; VISUAL DISORDER; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HEMATOLOGY; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PREGNANCY; RECURRENCE; REMISSION INDUCTION; RISK;

EID: 21244446981     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Tallman MS, Brenner B, Serna Jde L, Dombret H, Falanga A, Kwaan HC, et al. Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk Res 2005;29:347-51.
2. Falini B, Flenghi L, Fagioli M, Lo Coco F, Cordone I, Diverio D, et al. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (Anti-PML). Blood 1997;90:4046-53.
3. Villamor N, Costa D, Aymerich M, Esteve J, Carrio A, Rozman M, et al. Rapid diagnosis of acute promyelocytic leukemia by analyzing the immunocytochemical pattern of the PML protein with the monoclonal antibody PG-M3. Am J Clin Pathol 2000;114:786-92.
4. Samoszuk MK, Tynan W, Sallash G, Nasr S, Monczak Y, Miller W. An immunofluorescent assay for acute promyelocytic leukemia. Am J Clin Pathol 1998;109:205-10.
5. Gomis F, Sanz J, Sempere A, Plume G, Senent ML, Perez ML, et al. Immunofluorescent analysis with the anti-PML monoclonal antibody PG-M3 for rapid and accurate genetic diagnosis of acutepromyelocytic leukemia. Ann Hematol 2004;83:687-90.
6. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999;94:1192-200.
7. Tallman MS, Nabhan Ch, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002;99:759-67.
8. Sanz MA, Martin G, Lo Coco F. Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukemia. Baillieres Best Pract Res Clin Haematol 2003;16:433-51.
9. De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, et al. Additional chromosomal abnormalities have no effect on the clinical outcome of patients with acute promyelocytic leukemia. The European APL Group. Br J Haematol 2000;111:801-6.
10. Hernández JM, Martín G, Gutiérrez NC, Cervera J, Ferro MT, Calasanz MJ, et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica 2001;86: 807-13.
11. Cervera J, Martin G, Hernandez JM. Additional chromosome abnormalities have no prognostic value in acute promyelocytic leukemia patients treated with simultaneous ATRA and anthracycline-based chemotherapy: an update of the LPA96 and LPA99 PETHEMA protocols. Blood 104 Suppl 1:557[Abstract].
12. Frankel SR, Eardley A, Heller G, Berman E, Miller WH Jr, Dmitrovsky E, et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York study. Ann Intern Med 1994; 120:278-86.
13. Sanz M, Martin G, Gonzalez M, Leon A, Rayon C, Rivas Cm et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004;103: 1237-43.
14. Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. Leukemia 1995;9:774-8.
15. Specchia G, Lo Coco F, Vignetti M, Avvisati G, Fazi P, Albano F, et al. Extra-medullary involvement at relapse in acute promyelocytic leukemia patients treated or not with ATRA. A report by the GIMEMA Group. J Clin Oncol 2001;19:4023-8.
16. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997;90:1014-21.
17. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH, on behalf of the MRC Adult Leukemia Working Party. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999;93: 4131-43.
18. Sanz MA, Martín G, Rayón C, Esteve J, Gonzalez M, Diaz-Mediavilla JM, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. Blood 1999;94: 3015-21.
19. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999;94:12-22.
20. Grimwade D, Lo Coco E Acute promyelocytic leukemia: A model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002;16:1959-73.
21. Cheson BD, Bennett JM, Kopecky K, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-9.
22. Lo Coco F, Avvisati G, Vignetti M. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: results of the AIDA-2000 trial of the Italian GIMEMA group. Blood 2004;104:392[abs tract].
23. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T, et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study or the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:1247-53.
24. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1021-8.
25. Muindi J, Frankel SR, Miller WH, Jakubowski A, Scheinberg DA, Young CW, et al. Continuous treatment with all-trans RA progressively decreases plasma drug concentrations: implications for relapse and resistance in acute promyelocytic leukemia. Blood 1992;79: 299-307.
26. Avvisati G. The Italian way of treating acute promyelocytic leukemia. Blood 2003;102(Suppl 1):142[Abstract].
27. Breccia M, Diverio D, Noguera NI, Visani G, Santoro A, Locatelli F, et al. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy. Haematologica 2004;89:29-33.
28. Mandelli F, Latagliata R, Avvisati G, Fazi P, Rodeghiero F, Leoni F, et al. Treatment or elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukaemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 2003;17:1085-90.
29. Sanz MA, Vellenga E, Rayon C, Diaz-Mediavilla J, Rivas C, Amutio E, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004;104:3490-3.
30. Estey EH, Garcia-Manero G, Ferrajoli A. Use of all-trans retinoic acid + arsenic trioxide to eliminate or minimize use of chemotherapy in untreated acute promyelocytic leukemia. Blood 2005;104:393[abstract].
31. Mann G, Reinhardt D, Ritter J, Hermann J, Schmitt K, Gadner H, et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol 2001;80:417-22.
32. De Botton S, Coiteux V, Chevret S, Rayon C, Vilmer E, Sanz M, et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol 2004;22:1404-12.
33. Ortega JJ, Martin G, Madero L. Treatment with all-trans retinoic acid and anthracycline monochemotherapy in children with acute promyelocytic leukemia: a multicenter study by the PETHEMA group. Blood. 2003;102 Suppl 1:619[Abstract].
34. Testi AM, Biondi A, Lo Coco F, Moleti ML, Giona F, Vignetti M, et al. GIMEMA AIEOP AIDA protocol for the treatment of newly diagnosed promyelocytic leukemia in children. Blood 2005;1:Jan 27 [Epub ahead of print].
35. Mahmoud HH, Hurwitz CA, Roberts WM, Santana VM, Ribeiro RC, Krance RA, et al. Tretinoin toxicity in children with acute promyelocytic leukemia. Lancet 1993;342:1394-5.
36. Fadilah SAW, Hatta AZ, Keng CS, Jamil MA, Singh S. Successful treatment of acute promyelocytic leukemia in pregnancy with all-trans retinoic acid. Leukemia 2001;15:1665-6.
37. Lipovsky MM, Biesma DH, Christiaens GCML, et al. Successful treatment of acute promyelocytic leukemia with all-trans retinoic acid during late pregnancy. Br J Haematol 1996;94:699-701.
38. Terada Y, Shindo T, Endoh A, Watanabe M, Fukaya T, Yajima A. Fetal arrhythmia during treatment of pregnancy-associated acute promyelocytic leukemia with all-trans retinoic acid and favourable outcome. Leukemia 1997;11:454-5.